CAP-IT Center for LNP RNA Immunoprevention

CAP-IT LNP RNA 免疫预防中心

• 批准号: 10505675
• 负责人: NASSER Khaled ALTORKI
• 金额: $ 118.06万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10505675
• 关键词: Antigens; Architecture; Autologous; Award; Biotechnology; COVID-19; COVID-19 vaccine; Cancer Burden; Cessation of life; Clinic; Clinical; Clinical Trials; Clonal Evolution; Communicable Diseases; Computer Analysis; Data; Databases; Division of Cancer Prevention; Ensure; Genomics; Goals; Health Insurance Portability and Accountability Act; Hereditary Nonpolyposis Colorectal Neoplasms; Immune; Immunologic Surveillance; Immunoprevention; In Vitro; Individual; Infection; Inherited; Intercept; Lesion; Lung; Lung Adenocarcinoma; Malignant Neoplasms; Medical; Neisseria meningitidis; Nodule; Patients; Poliomyelitis; Predisposition; Premalignant Neoplasm; Prevention; Prevention strategy; Primary Cancer Prevention; RNA; RNA vaccination; RNA vaccine; Recording of previous events; Recurrence; Research; Resource Sharing; Role; Science; Services; Smoker; Sum; Syndrome; T-Lymphocyte; Technology; Translating; Tumor Antigens; Vaccines; Validation; Work; biobank; cancer genetics; cancer genome; cancer genomics; cancer immunotherapy; cancer predisposition; cancer prevention; cancer risk; clinical translation; cytotoxicity test; efficacy testing; experience; flexibility; immune RNA; immunogenic; immunogenicity; in vivo; in vivo Model; individualized prevention; innovation; lipid nanoparticle; mouse model; neoantigens; patient population; pre-clinical; programs; success; transcriptome; tumor; tumor immunology; vaccine discovery; vaccine formulation

Overall Component: Project Summary/Abstract The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer risk. The PI is Dr. Lipkin, an established leader in Cancer Prevention who has made several important, clinically translated contributions to the field. Project 1 will develop and validate an LNP RNA immunoprevention vaccine for Lynch syndrome, a genetic cancer predisposition syndrome with highly immunogenic recurrent neoantigens shared among cancers from different patients. Project 2 will develop and validate an LNP RNA immune interception vaccine for patients with lung non-solid nodule (NSN) pre-malignant neoplasms, a lung adenocarcinoma precursor lesion. To achieve these goals, we will use state-of-the-art technologies, including LNP RNA vaccine formulation, computational genomic tumor immunology, spatial genomics and immunopeptidomics. To ensure CRI's scientific rigor and excellence, we have assembled a scientifically outstanding CRI External Advisory Board (EAB), which includes 2021 Lasker Award winner Drew Weissman (Penn) for his work on LNP RNA COVID19 vaccines. Overall, the CAP-IT CRI will develop state-of-the-art LNP RNA immunoprevention and immune interception vaccines and provide a technologically powerful platform to jumpstart additional CAP-IT CRI LNP RNA vaccine projects. We anticipate that CAP-IT CRI will propel both Lynch syndrome and lung NSN vaccines to NCI PREVENT and CP-NET clinical trials within the next 5 years and FDA approval/clinical translation within ten years.

总体构成：项目摘要/摘要 CAP-IT RNA免疫预防中心(CRI)的总体目标是在临床前描述、制定和 验证脂质纳米粒子RNA(LNP RNA)疫苗对癌症增加患者的精确预防 风险。PI是利普金博士，他是癌症预防领域的知名领导者，他在临床上做出了几项重要的 对该领域的翻译贡献。项目1将开发和验证LNP RNA免疫预防疫苗 对于Lynch综合征，一种具有高度免疫原性的复发新抗原的遗传性癌症易感综合征 在不同患者的癌症之间共享。项目2将开发和验证LNP RNA免疫 肺非固体结节(NSN)癌前病变患者的拦截疫苗 腺癌前驱病变。为了实现这些目标，我们将使用最先进的技术，包括 核糖核酸疫苗配方，计算基因组肿瘤免疫学，空间基因组学和 免疫药物学。为了确保CRI的科学严谨和卓越，我们已经组装了一个科学的 杰出的CRI外部顾问委员会(EAB)，其中包括2021年拉斯克奖获得者德鲁·魏斯曼 (宾夕法尼亚大学)表彰他在LNP RNA COVID19疫苗方面的工作。总体而言，CAP-IT CRI将开发最先进的LNP RNA 免疫预防和免疫拦截疫苗，并提供一个技术强大的平台 启动额外的CAP-IT CRI LNP RNA疫苗项目。我们预计CAP-IT CRI将推动这两项 Lynch综合征和肺NSN疫苗将在未来5年内进行NCI预防和CP-Net临床试验 并在十年内获得FDA批准/临床翻译。